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ABSTRACT
Mutations in the androgen receptor (AR) gene result in a wide
range of phenotypes of the androgen insensitivity syndrome (AIS).
Inter- and intrafamilial differences in the phenotypic expression of
identical AR mutations are known, suggesting modifying factors in
establishing the phenotype.
Two 46,XY siblings with partial AIS sharing the same AR gene
mutation, R846H, but showing very different phenotypes are studied.
Their parents are first cousins. One sibling with grade 5 AIS was
raised as a girl; the other sibling with grade 3 AIS was raised as a boy.
In both siblings serum levels of hormones were measured; a sex
hormone-binding globulin (SHBG) suppression test was completed;
and mutation analysis of the AR gene, Scatchard, and SDS-PAGE
analysis of the AR protein was performed. Furthermore, 5a-reductase
2 expression and activity in genital skin fibroblasts were investigated,
and the 5a-reductase 2 gene was sequenced.
The decrease in SHBG serum levels in a SHBG suppression test did
not suggest differences in androgen sensitivity as the cause of the
phenotypic variation. Also, androgen binding characteristics of the
AR, AR expression levels, and the phosphorylation pattern of the AR
on hormone binding were identical in both siblings. However, 5a-
reductase 2 activity was normal in genital skin fibroblasts from the
phenotypic male patient but undetectable in genital skin fibroblasts
from the phenotypic female patient. The lack of 5a-reductase 2 ac-
tivity was due to absent or reduced expression of 5a-reductase 2 in
genital skin fibroblasts from the phenotypic female patient. Exon and
flanking intron sequences of the 5a-reductase 2 gene showed no mu-
tations in either sibling. Additional intragenic polymorphic marker
analysis gave no evidence for different inherited alleles for the 5a-
reductase 2 gene in the two siblings. Therefore, the absent or reduced
expression of 5a-reductase 2 is likely to be additional to the AIS.
Distinct phenotypic variation in this family was caused by 5a-
reductase 2 deficiency, additional to AIS. This 5a-reductase deficiency
is due to absence of expression of the 5a-reductase iso-enzyme 2 as
shown by molecular studies. The distinct phenotypic variation in AIS
here is explained by differences in the availability of 5a-dihydrotes-
tosterone during embryonic sex differentiation. (J Clin Endocrinol
Metab 86: 1240–1246, 2001)
ANDROGEN INSENSITIVITY SYNDROME (AIS) is anX-linked disorder of male sexual differentiation,
caused by a defective or absent androgen receptor (AR; re-
viewed in Ref. 1). Mutations in the AR gene result in a wide
range of AIS phenotypes. The phenotypic spectrum in 46,XY
individuals ranges from a complete female phenotype with
testes [complete AIS (CAIS)], through female phenotypes
with clitoromegaly or posterior fusion of the labia minora, to
a male phenotype with hypospadias and/or micropenis and
gynaecomastia, or even a normal male phenotype with in-
fertility, all defined as partial AIS (PAIS) (1). The finding of
more than 150 different AR gene mutations in over 250 AIS
patients (2) illustrates the genetic heterogeneity in AIS.
The AR is a transcription factor that binds either testos-
terone (T) or 5a-dihydrotestosterone (DHT); however, DHT
is bound with higher affinity and has a slower dissociation
rate from the receptor than T (3–5). When androgen is bound
to the AR, the complex dimerizes and migrates into the
nucleus where it recruits transcription factors and binds to
the promoter region of androgen-sensitive target genes (6).
With the advent of molecular analysis of the AR gene it
was hoped that a correlation between a molecular defect and
a particular phenotype could be established. Such a relation-
ship would enable prediction of the response to androgen
therapy in infants with PAIS, relevant for not only long-term
psychosexual outcome but also for genetic counseling of
parents and other identified female carrier relatives. Ten
years after cloning of the AR gene (7–10), it is obvious that
there is no simple genotype-phenotype relationship in this
phenotypically and genotypically heterogeneous syndrome.
Identified mutations are associated with different pheno-
types in the same kindred (11–14) or rarely with CAIS in one
kindred and with PAIS in another (2). Therefore, additional
factors apparently may influence the effect of the mutant
receptor on the development of the external genitalia.
Reduced 5a-reductase 2 activity has been described in the
70s and 80s in AIS families and has been suggested to be the
cause of the observed phenotypic variation (15–17). At that
time, molecular evaluation of the AR and 5a-reductase 2
genes was not yet available.
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Here, a family with distinct phenotypes in two siblings
with the same AR gene mutation is reported. The identified
mutation in the AR gene, R846H (amino acid numbering
based on 20 glutamine residues and 16 glycine residues, thus
a total of 910 amino acids) is a frequently identified mutation
(2). Experimental evidence is provided for a different avail-
ability of DHT in these two siblings.
Subjects and Methods
In a nationwide study on the genotype/phenotype relationship in
AIS, we studied a family with eight children, of whom two were affected
with AIS (Fig. 1). The parents (subjects I-1 and I-2; Fig. 1) were of
Moroccan descent and first cousins: their fathers were brothers. There
was no family history of ambiguous genitalia.
Subject II-5 was a 13-yr-old pubertal female patient, with not yet fully
developed breasts, few pubic hairs, and no axillary hair (Tanner stage
M3, P2, A0), a female habitus, and female voice. She was studied after
her brother was diagnosed with AIS. The karyotype was 46,XY. External
genitalia were a normally sized clitoris, normal labia majora, posterior
fusion of the labia minora leading to an urogenital sinus (Fig. 2A), and
a shallow (2.5 cm in length), blindly ending vagina that was connected
with the urogenital sinus. Testes were localized bilaterally in the ingui-
nal region. The following serum levels of hormones were determined:
T, 13.5 nmol/L (range in normal males, 10–30 nmol/L); DHT, 1.55
nmol/L; T/DHT, 8.7 (normal males, ,10); estradiol, 35 pmol/L (normal
males, 50–200 pmol/L); and LH, 5.7 U/L (normal males, 1.5–8 U/L). In
accordance with her personal wish, she was not gonadectomized until
2 yr later, at age 15.5 yr. Normally developed epididymides and vasa
deferentia were found. Mu¨llerian duct derivatives were absent. Serum
hormone levels at that time were: T, 31.5 nmol/L; DHT, 2.42 nmol/L;
T/DHT, 13; estradiol, 156 pmol/L; and LH, 8.4 U/L. Her voice had
remained high-pitched, the clitoral size remained normal, pubic hair had
remained Tanner stage P2, axillary hair was still absent, and her breasts
had grown to M4. T and DHT, measured every 6 months from age 13.5
yr, showed T/DHT ratios between 8.6 and 13.0. From age 14, T had been
above 30 nmol/L.
Subject II-8 (Fig. 1), karyotype 46,XY, was born with perineoscrotal
hypospadias, a micropenis with well developed corpora cavernosa, a
bifid scrotum containing testes, and transposition of the scrotum (Fig.
2B). Mu¨llerian duct remnants were absent, as was established by ultra-
sound. Bilaterally epididymides were palpable. Serum hormone levels
measured at age 4 days: T, 0.64 nmol/L. Seventy-two hours after 1500
U human CG (hCG) im, T was 18 nmol/L. He was assigned the male sex.
At 5 yr of age his basal serum levels were: LH, 0.1 U/L; T, 0.1 nmol/L;
and DHT, ,0.1 nmol/L. Seventy-two hours after 1500 U hCG im: T, 11.8
nmol/L; DHT, 2.1 nmol/L; T/DHT, 5.6. All values are within the normal
range for this age.
I-1 and II-3 were normally virilized healthy adult males. II-6 was a
normal healthy prepubertal boy with a normal penis length and a nor-
mal testis volume for his age. The mother, subject I-2, had a gonadal/
somatic mosaı¨cism for the AR mutation as was shown by segregation
analysis of the different AR alleles among affected and nonaffected
family members and by allele-specific oligonucleotide analysis, respec-
tively, as described previously (18).
The medical ethical committee of the University Hospital Rotterdam
approved the protocol of this study.
SHBG suppression test
Androgen sensitivity in the liver can be measured in vivo with use of
an SHBG suppression test. We have used the protocol described by
Sinnecker et al. (19): Stanozolol (0.2 mg/kg/day, single evening dose)
was administered orally at days 0, 1, and 2. Blood samples were taken
before and at days 5, 6, 7, and 8 after the start of the test. The initial SHBG
serum level was compared with the lowest level obtained after admin-
istration of Stanozolol (days 5, 6, 7, and 8) and expressed as a percentage
of the initial value. In normal controls the SHBG serum level after
Stanozolol declined to 35.6–62.1% (range) of the initial value. However,
in patients with CAIS, the SHBG serum level remained unchanged, and
in PAIS patients the SHBG level declined to 48.6–89.1% (range) of the
initial value (19).
AR gene mutation detection
Genomic DNA was isolated from peripheral blood leukocytes and
from cultured genital skin fibroblasts, following standard procedures
(20).
Exon and flanking intron sequences were screened for mutations in
the AR gene with the use of PCR-single-strand conformational poly-
morphism (21). PCR fragments suspected to harbor mutations were
analyzed by direct sequencing (22). Furthermore, in DNA isolated from
genital skin fibroblasts, the entire AR gene of subject II-5 was sequenced.
AR gene CAGn(CAA)/GGN repeat length
CAGn(CAA) and GGN repeat lengths in exon 1 of the AR gene,
encoding poly-glutamine and poly-glycine stretches, respectively, were
determined as described previously (21, 22).
Cell culture
Skin biopsies were taken either during surgical correction of the
external genitalia, or gonadectomy or circumcision. Genital skin fibro-
blasts were derived from biopsies of the fusion line of the labia minora
of subject II-5 of control individuals, and from scrotal skin of subject II-8
and from preputium of a normal prepubertal boy obtained at circum-
cision. Furthermore, genital skin fibroblasts were analyzed from biop-
sies from preputium of a prepubertal 5a-reductase 2-deficient patient
with clitoromegaly and posterior fusion of the labia minora. This patient
had a T/DHT ratio after hCG of 16.5. All cell lines were cultured as
described previously (22), with modifications as described with the
experiments.
Androgen characteristics of the AR
Whole cell Scatchard analysis was performed on genital skin fibro-
blasts, as described previously (22). Genital skin fibroblast (GSF) 1 was
used from subject II-5.
SDS-PAGE of the AR
Confluent cell layers in 150 cm2 culture flasks, were cultured in
serum-free medium for 24 h, followed by 24 h in medium containing
increasing concentrations (0, 5, 30, and 100 nm) of the synthetic, non-
metabolizable androgen methyltrienolone (R1881). GSF 1 was used from
subject II-5. Whole cell lysates were prepared, immunoprecipitated,
separated on a SDS-PAGE gel, and immunostained as described pre-
viously (22).
FIG. 1. Compacted pedigree of the family described. A square with the
number 3 in the center means three males. A circle with number 2 in
the middle means two females. The affected individuals are indicated
with black circles or black squares according to their phenotypic ap-
pearance and not according to their genetic sex.
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5a-Reductase 2 assay
5a-Reductase 2 activity can be influenced by either clonal origin of the
cell line (23) or by the site of origin of the biopsies (24). Therefore, two
different GSF cell lines from subject II-5 (GSF 1 and 2) derived from
separate biopsies taken 1.5 yr apart were used for the studies.
GSF cell lines derived from biopsies from subject II-8, from a normal
male, from a normal female, and from a 5a-reductase 2-deficient patient
homozygous for a known pathogenic mutation in the 5a-reductase 2
gene (H231R) were used as controls.
Because 5a-reductase 2 activity increases with serial subcultures (25,
26), all cell lines used were the seventh subculture.
To reduce possible bias by confluency rate, all cell lines were grown
in 75-cm2 culture flasks with medium containing 10% FCS. They were
harvested 7 days after subculture. At that time, the cell lines were
confluent and the flasks contained ;1.2 3 106 cells.
Harvesting of cells. Cells were washed multiple times with PBS and with
20 mm Tris saline (pH 7.4), then scraped in Tris saline and pelleted at
800 3 g. Pellets were washed twice in Tris saline. Cell-free extracts were
prepared by four cycles of freezing in liquid nitrogen and thawing.
Enzyme assay. Forty microliters of cell-free extracts were incubated with
10 ml of 30 mm NADPH and 50 ml reaction mixture [reaction mixture
consisted of 500 ml of 10 mm Tris citrate (pH 5.5), 2.4 pmol 1,2,6,7
3H-testosterone (Amersham Pharmacia Biotech, Little Chalfont, UK),
and 7.6 pmol testosterone (Steraloids)] at 37 C for 1 h. The reaction was
stopped on ice. Each incubation was done in duplicate. Assays were
done in triplicate.
To all samples 10 ml of a steroid mixture containing androstanedione,
androstenedione, DHT, testosterone, 3a-androstanediol, each 1 mg/mL
ethanol, were added, before extraction of radioactivity with a total of 3 3
500 mL ethylacetate. Extracts were evaporated to dryness, and the res-
idues were dissolved in 50 ml ethanol and chromatographed in dichlo-
romethane:ethylacetate:methanol (85:15:3) on a 0.25-mm layer silica gel
plate, 20 3 20 cm (Merck, Darmstadt, Germany). Steroids were visual-
ized in a control lane by spraying with 20% H2SO4 in methanol and
developing at 100 C for 15 min. Fractions were collected in separate vials,
resuspended in 500 ml ethanol, and were counted in a liquid scintillator
counter. 5a-Reductase activity was calculated from the sum of 3H-
radioactivity in the androstanediol, DHT, and 3a androstanediol fractions
divided through the sum of 3H radioactivity in the androstanediol, andro-
stenediol, DHT, T, and 3a androstanediol fractions. The amount of protein
in each cell-free extract was determined according to Bradford (27).
5a-Reductase activity was expressed as femtomoles of 5a reduced
steroids formed per milligram of protein per hour.
Analysis of the 5a-reductase 2 gene and polymorphic
marker analysis
Exon and flanking intron sequences of the 5a-reductase type 2 gene
(SRD5A2) from subject II-5 were analyzed with direct sequencing after
amplification of fragments with primers described by Hiort et al. (27). As
an intragenic polymorphic marker, codon 89 in exon 1 of the SRD5A2
gene was used. This codon is either CTA or GTA with unknown allele
frequencies (29, 30). Genomic DNA isolated from GSF 1 (subject II-5) and
GSF (subject II-8) was used.
RT-PCR of 5a-reductase 2 messenger RNA (mRNA)
Total RNA was extracted from GSF cell lines using Trizol reagent (Life
Technologies, Inc., Breda, The Netherlands) and quantified by absorp-
tion at 260 nm. Complementary DNA (cDNA) was synthesized from 2.5
mg RNA with the use of an oligo dT primer (Promega Corp., Madison,
WI). Of each investigated cell line, cell pellets from different cell culture
flasks were pooled and divided in equal aliquots. RNA was isolated
from these aliquots in separate experiments. The various aliquots of
RNA were subjected to several independent RT-PCR experiments.
As a control for cDNA synthesis, b 10 actin was used. b Actin was
amplified with antisense primer GAGGTAGCAGGTGGCGTTTAC-
GAAGAT and sense primer AAGGATTCCTATGTGGGCGACGAG.
Primers used for amplification of the 5a-reductase 2 gene were: antisense
primer 5B, 59-TGACAGTTTTCATCAGCATTG-39 specific for 39 un-
translated sequences in exon 5; and sense primer 120A, 59-CACTG-
GAAATGGAGTCCTTC-39, starting at codon 120 in exon 2. These prim-
ers were used in a PCR reaction as described below.
Three microliters of the obtained cDNA reaction product was used in
a 50-ml PCR amplification reaction. The 50-mL PCR reaction mix con-
tained 1.5 mm MgCl2. Conditions for the PCR reactions in a Biometra
FIG. 2. External genitalia of subject II-5 at age 15.5 yr (A) and subject II-8 at 1 month of age (B).
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cycle sequencer were: hot start at 94 C for 5 min, then 35 cycles at 94 C
for 1 min, at 55 C for 30 sec, at 72 C for 1 min, and final extension for
10 min at 72 C. The PCR product was visualized after electrophoresis on
a 2% agarose gel that contained ethidium bromide. Amplification of
genomic DNA was prevented because intervening introns were in to-
tal ; 7.3 kb in size, and the Amplitaq polymerase (Perkin-Elmer Corp.,
Norwalk, CT) cannot amplify DNA of this size under the used
conditions.
The resulting PCR product was subcloned into a plasmid using the
TOPO TA cloning kit (Invitrogen, San Diego, CA) and subjected to auto-
mated sequencing.
Results
SHBG suppression test
An SHBG suppression test (19) showed a maximal de-
crease in SHBG of 73.5% on days 5, 6, 7, and 8 in the female
patient, subject II-5 [normal males, ,63.4%; PAIS, 63.4–93%;
CAIS, .92% (31)], whereas a maximal decrease of 92% on
day 7 was seen in subject II-8. It can be concluded that both
siblings display a suppression in the PAIS range.
Mutation detection and identification in the AR gene
With PCR-single-strand conformational polymorphism,
followed by direct sequencing of the AR gene, mutation
R846H in the ligand-binding domain of the AR was identi-
fied in both individuals II-5 and II-8. No other mutations
were identified on sequencing of the exon and flanking in-
tron sequences of the AR gene of subject II-5.
Length of (CAG)nCAA and GGN repeats
In both siblings the (CAG)nCAA and GGN repeats in exon
1 of the AR gene mutant-allele carried 14 glutamine and 24
glycine residues (18), respectively.
AR binding characteristics
AR binding characteristics in GSF of subjects II-5 and II-8
(Table 1) show an increased equilibrium dissociation con-
stant (Kd) but a normal number of binding sites (Bmax). The
difference in Bmax and Kd values between the two siblings
should be interpreted as a variance of Scatchard analysis.
Hormone-dependent AR phosphorylation
AR protein isolated from wild-type cells cultured in the
absence of androgens migrates as a doublet of 110 and 112
kDa during SDS-PAGE. These represent an unphosphory-
lated AR isotype and a phosphorylated AR isotype, respec-
tively. On binding of androgens, the AR undergoes addi-
tional phosphorylation, resulting in a third isoform of 114
kDa. AR mutants that are either partially defective in ligand
binding or in DNA binding or in transcription activation,
migrate with a reduced amount of the 114 kDa isoform dur-
ing SDS-PAGE (Ref. 31; Fig. 3). At a relatively low androgen
concentration of 5 nm R1881, GSFs of II-5 and II-8 express
equally reduced amounts of the third isoform of 114 kDa
compared with the wild type. Increased androgen levels did
not induce the 114-kDa band as in the wild-type cells (Fig. 3).
Moreover, both siblings have an equally deficient hormone
induced upshift of the 114 kDa AR isoform. A deficient
hormone induced upshift is in agreement with the increased
dissociation of the AR hormone complex in GSF of both
patients.
5a-Reductase 2 activity
Of subject II-5, two different GSF cell lines were deficient
in 5a-reductase 2, similar as in a 5a-reductase 2-deficient
patient homozygous for SRD5A2 mutation H231R. How-
ever, sibling II-8 had normal 5a-reductase 2 activity in GSF
(Table 2).
Analysis of the 5a-reductase 2 gene and polymorphic
marker analysis
No mutations were found in the 5a-reductase type 2 gene
of subjects II-5 and II-8 on sequencing exon and flanking
intron sequences.
Both siblings were heterozygous for a known polymor-
phism in exon 1 of the 5a-reductase 2 gene, CTA/GTA, codon
89 (data not shown). A homozygous defect in the 5a-reduc-
tase 2 gene, inherited from the consanguineous parents and
present in other parts of the gene than the sequenced parts
such as introns or in a gene promoter, is, therefore, very
unlikely.
5a-Reductase 2 mRNA expression
After RT-PCR of 5a-reductase 2 mRNA using a primer
combination, as outlined in Subjects and Methods, a 460-bp
fragment can be expected. No 5a-reductase 2 cDNA was
detectable after RT-PCR of total RNA preparations from
GSFs 1 and 2 of subject II-5, whereas in total RNA prepara-
tions from the GSF of subject II-8 a band of 460-bp was
detected (Fig. 4). This band was subcloned and sequenced
and exhibited the wild-type 5a-reductase 2 gene sequence.
Therefore, the absence of 5a-reductase type 2 activity in GSFs
of subject II-5 is most likely due to lack of or reduced ex-
pression of 5a-reductase type 2.
Discussion
In this family, a very different phenotypic expression of
AIS is observed in siblings carrying the same mutation in the
AR gene. Additional mutations in the AR gene or differences
in the length of the polyglutamine or polyglycine repeats
were not found. AR gene promoter mutations are very un-
likely because AR protein expression is similar and normal
in both siblings. Furthermore, phosphorylation of the AR on
hormone binding, was equally reduced in genital skin fibro-
TABLE 1. Scratchard analysis of the AR in GSFs of both affected siblings
Subject II-5, female
phenotype
Subject II-8, male
phenotype Normal values
Bmax (fmol/mg protein) 87 61 .20
Kd (nM) 0.9 0.5 ,0.1
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blasts of both siblings, irrespective whether low or high con-
centrations of the nonmetabolizable androgen R1881 were
used. Phosphorylation of the AR occurs during DNA binding
of the ligand-AR complex on hormone-responsive elements
and during or following transcription of androgen-regulated
genes (31). The equally reduced phosphorylation of ARs and
comparable clinical androgen responsiveness in both sib-
lings, as determined by SHBG suppression tests, provide
evidence that the AR itself is not responsible for the distinct
variation in phenotype and suggest an important role for
factors other than the AR in determining the phenotype.
5a-Reductase activity was found to be totally absent in
genital skin fibroblasts of subject II-5 (Table 2). DHT, formed
in the embryonal urogenital tissues by 5a-reductase 2, causes
elongation and enlargement of the urogenital tubercle and
fusion of the urogenital swellings and folds during the de-
velopment of the embryo (32, 33). We hypothezised that the
phenotypic differences between the siblings might be due to
the difference in availability of DHT, especially because both
siblings carry a particular mutant AR (R846H). When this
R846H mutant AR is stimulated with DHT instead of tes-
tosterone, the transcriptional deficit becomes less (34, 35) and
the functional defect can even be partially corrected by the
repeated addition of DHT (34). Therefore, a difference in
availability of DHT between the two siblings could have been
of particular influence on the phenotype.
Although, serum dihydrotestosterone levels at puberty in
subject II-5 are low but detectable and once fell within the low
normal range, similar DHT serum levels are found in pu-
bertal/adult 5a-reductase 2-deficient patients with deficient
5a-reductase 2 activity as established in GSFs (16, 36). When
5a-reductase 2-deficient patients enter puberty they start to
synthesize some DHT. The source of this DHT may be either
peripheral conversion by 5a-reductase type 1 in the liver and
skin or, in some cases, residual activity of the mutant
enzyme.
A 5a-reductase 2 deficiency secondary to the primary de-
FIG. 3. Hormone-dependent AR phosphorylation in GSFs. GSFs of both siblings (II-5 and II-8) and a normal prepubertal boy (WT) were cultured
in the absence or presence of increasing concentrations (0–100 nM) of the nonmetabolizable androgen R1881. The molecular sizes of the AR
isoforms are indicated at the left (110, 112, and 114 kDa). AR protein isolated from wild-type cells cultured in the absence of androgens migrates
as a doublet of 110 and 112 kDa, representing an unphosphorylated 110 kDa AR isotype and a phosphorylated 112 kDa AR isotype, respectively.
On binding of androgens, the AR undergoes additional phosphorylation, resulting in a third isoform of 114 kDa. At a relative low androgen
concentration of 5 nM R1881, GSFs of siblings II-5 and II-8 have equally reduced amounts of the third isoform of 114 kDa compared with the
wild type. Increased androgen levels did not induce the 114-kDa band as in the wild-type cells, and both siblings have an equally deficient
hormone-induced upshift of the 114-kDa AR isoform.
TABLE 2. 5a-Reductase 2 activities in GSFs from control persons
and 46,XY patients with AIS or 5a-reductase 2 deficiency
Subject/disorder Age at biopsy(yr)
5a-reductase
2 activity
(pmol/mg protein/h)a
No. of
experiments
Mean Range
Normal male 1 73 44–139 6
Normal female 16 41 1
II-5 GSF 1; PAIS 13 0.2 0–0.3 2
II-5 GSF 2; PAIS 15 0 0–0 2
II-8; PAIS 5 88 42–154 5
5a-Reductase 2
deficiency
4 0.4 0–1.3 3
In all assays the recovered radioactivity represented at least 84%
of the added 3H-testosterone. All assays were done in duplicate, vari-
ation between duplicate measurements was ,11%.
a Mean and range are given. Ranges in different experiments are
shown.
FIG. 4. RT-PCR of 5a-reductase 2 mRNA. RNA extracted from GSFs
1 and 2 of subject II-5 and RNA from the GSF of subject II-8 was used.
b Actin expression was used as a control for cDNA synthesis. The
amplified 5a-reductase 2 cDNA fragment, 460 bp in size, is indicated
with an arrow.
1244 BOEHMER ET AL. JCE & M † 2001
Vol. 86 † No. 3
 at Medical Library Erasmus MC on November 28, 2006 jcem.endojournals.orgDownloaded from 
fect AIS has been reported to cause phenotypic differences in
other families with AIS and was established by 5a-reductase
2 assays in GSFs and by hormonal analysis in serum (15–17).
It has been suggested that in AIS patients 5a-reductase 2
enzyme activity is preserved in the liver but deficient in the
periphery, in contrast to the autosomal recessive inherited
syndrome of 5a-reductase 2 deficiency wherein a general-
ized severe defect of both hepatic and peripheral 5a-reduc-
tase is found (16, 37). These observations were made before
cloning of the AR and 5a-reductase 2 genes (7, 10, 29, 38). The
nature of the decreased 5a-reductase 2 activity remained
unidentified. The repeated observation of this 5a-reductase
2 deficiency secondary to AIS and the identification of a
mutant AR, which is especially dependent on DHT for re-
sidual androgen action, provides a basis for further studies
on secondary 5a-reductase 2 deficiency.
RT-PCR experiments in this family show that the 5a 10
reductase 2 deficiency in GSFs of subject II-5 is due to re-
duced expression of the 5a-reductase 2 gene (SRD5A2). A
homozygous defect in the SRD5A2 gene inherited from the
consanguineous parents was excluded as no mutations in the
SRD5A2 gene were found in both siblings. The presence of
mutations in the remaining intronic sequences or the pro-
moter region of the SRD5A2 gene is very unlikely because
both siblings are heterozygotes for the CTA/GTA polymor-
phism in exon 1.
With molecular means we show that the additional 5a-
reductase 2 deficiency in the presented subject II-5 with AIS
is due to absent or reduced expression of the 5a-reductase 2
enzyme.
The etiology of this additional 5a-reductase 2 deficiency is
not clear. One possible explanation is disruption of a feed
forward control mechanism: formation of trace amounts of
DHT that are bound to the AR induces 5a-reductase 2 activity
thereby increasing DHT synthesis and triggering a positive
developmental cascade. Such a positive feedback mechanism
exists in the rat embryonic urogenital tract where 5a-reduc-
tase type 2 expression is increased by either T or DHT (39).
A positive feedback mechanism is also present in adult rat
prostate but is absent in embryonic rat prostate (39, 40). In
humans, the presence of such a positive regulation by an-
drogens is suggested by the presence of reduced 5a-reduc-
tase 2 expression in urogenital swellings and tubercles in
female fetuses. The expression of 5a-reductase 2 in female
fetuses is one third of the expression of 5a-reductase 2 found
in males, who have higher levels of androgens (36). Argu-
ments against positive regulation of 5a-reductase 2 enzyme
activity in humans are the observations that in many CAIS
patients 5a-reductase 2 activity is normal and during in vitro
culture of GSFs no increase of 5a-reductase activity is ob-
served after stimulation with androgen (24, 41, 42). In GSFs,
5a-reductase 2 is the predominantly expressed and active
iso-enzyme (43).
Others have suggested a unbalance between estrogen and
androgen action as the cause for secondary 5a-reductase
deficiency (16, 24).
An interesting possibility is an additional autosomal re-
cessively inherited defect in a factor regulating 5a-reductase
2 expression, inherited from the consanguineous parents by
subject II-5. Because 5a-reductase 2 expression appears in
fetal rats before testicular androgen synthesis starts, it was
suggested that the early regulation and most likely the initial
induction events are androgen independent in rat (38).
Which factors control the temporal and cell type-specific
pattern of 5a-reductase enzymes in the rat or in man is
presently unknown.
These observations support the hypothesis that differ-
ences in the availability of DHT in different target tissues
could lead to phenotypic variation between AIS patients who
carry the same AR gene mutation. This study shows that
distinct intrafamilial phenotypic variation can be associated
with additional 5a-reductase 2 deficiency, information to be
implemented in genetic counseling of families with andro-
gen insensitivity.
Additional 5a-reductase 2 deficiency was shown to be
associated with undetectable 5a-reductase 2 mRNA levels in
GSFs. The total lack of enzyme activity is unlikely to be due
to mutations in the 5a-reductase 2 gene itself. Possible causes
for this additional 5a-reductase 2 deficiency are a defective
autocatalyic regulation or an autosomal recessively inherited
defect in a regulatory protein that controls the cell type-
specific and temporal expression pattern of the 5a-reductase
2 gene.
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